Compare Stocks: SMLR, TNDM, AORT, and BVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$23.02 +1.7%	$26.15	$19.16 ▼ $48.25	$1.10B	1.25	631,701 shs	446,057 shs
BVS Bioventus	$14.02 +1.5%	$13.56	$6.37 ▼ $15.89	$1.16B	0.65	473,385 shs	588,665 shs
SMLR Semler Scientific	$20.33 -4.9%	$19.24	$14.89 ▼ $50.44	$310.74M	1.32	895,814 shs	1.62 million shs
TNDM Tandem Diabetes Care	$16.42 +4.5%	$19.63	$11.46 ▼ $29.65	$1.09B	1.55	1.96 million shs	2.85 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	0.00%	-2.92%	-15.21%	+0.99%	-44.61%
BVS Bioventus	0.00%	+6.97%	-0.22%	+41.21%	+107.36%
SMLR Semler Scientific	0.00%	0.00%	0.00%	0.00%	-28.19%
TNDM Tandem Diabetes Care	0.00%	-6.82%	-26.64%	-0.69%	+31.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$23.02 +1.7%	$26.15	$19.16 ▼ $48.25	$1.10B	1.25	631,701 shs	446,057 shs
BVS Bioventus	$14.02 +1.5%	$13.56	$6.37 ▼ $15.89	$1.16B	0.65	473,385 shs	588,665 shs
SMLR Semler Scientific	$20.33 -4.9%	$19.24	$14.89 ▼ $50.44	$310.74M	1.32	895,814 shs	1.62 million shs
TNDM Tandem Diabetes Care	$16.42 +4.5%	$19.63	$11.46 ▼ $29.65	$1.09B	1.55	1.96 million shs	2.85 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	0.00%	-2.92%	-15.21%	+0.99%	-44.61%
BVS Bioventus	0.00%	+6.97%	-0.22%	+41.21%	+107.36%
SMLR Semler Scientific	0.00%	0.00%	0.00%	0.00%	-28.19%
TNDM Tandem Diabetes Care	0.00%	-6.82%	-26.64%	-0.69%	+31.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	2.75	Moderate Buy	$44.83	94.76% Upside
BVS Bioventus	2.83	Moderate Buy	$16.80	19.83% Upside
SMLR Semler Scientific	2.00	Hold	N/A	N/A
TNDM Tandem Diabetes Care	2.48	Hold	$29.18	77.74% Upside

Current Analyst Ratings Breakdown

Latest SMLR, TNDM, AORT, and BVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	TNDM Tandem Diabetes Care	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$31.00 ➝ $28.00
9/8/2026	TNDM Tandem Diabetes Care	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	TNDM Tandem Diabetes Care	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/18/2026	AORT Artivion	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/17/2026	BVS Bioventus	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $19.00
8/17/2026	BVS Bioventus	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$15.00
8/11/2026	AORT Artivion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D-)
8/7/2026	TNDM Tandem Diabetes Care	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$30.00 ➝ $26.00
8/7/2026	TNDM Tandem Diabetes Care	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00
8/7/2026	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$17.00 ➝ $21.00
8/7/2026	TNDM Tandem Diabetes Care	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$441.33M	2.54	$1.12 per share	20.54	$9.46 per share	2.43
BVS Bioventus	$581.85M	2.03	$1.29 per share	10.83	$2.76 per share	5.08
SMLR Semler Scientific	$36.96M	8.41	$4.48 per share	4.54	$24.90 per share	0.82
TNDM Tandem Diabetes Care	$1.01B	1.13	N/A	N/A	$2.29 per share	7.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	$9.77M	-$0.07	N/A	29.90	N/A	-0.67%	6.07%	2.93%	11/5/2026 (Estimated)
BVS Bioventus	$22.73M	$0.77	18.21	15.75	1.76	9.36%	28.08%	9.82%	N/A
SMLR Semler Scientific	$40.90M	$2.78	7.31	N/A	N/A	130.80%	34.21%	25.58%	N/A
TNDM Tandem Diabetes Care	-$204.71M	-$0.93	N/A	164.20	N/A	-6.08%	-45.97%	-6.23%	11/5/2026 (Estimated)

Latest SMLR, TNDM, AORT, and BVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AORT Artivion	$0.0025	$0.13	+$0.1275	-$0.28	$119.99 million	$125.76 million
8/6/2026	Q2 2026	TNDM Tandem Diabetes Care	-$0.3207	-$0.31	+$0.0107	-$0.31	$254.99 million	$254.56 million
8/5/2026	Q2 2026	BVS Bioventus	$0.22	$0.22	N/A	$0.47	N/A	$153.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
SMLR Semler Scientific	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	0.82	3.47	2.51
BVS Bioventus	0.83	1.69	1.17
SMLR Semler Scientific	0.21	1.97	1.95
TNDM Tandem Diabetes Care	4.62	3.18	2.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
BVS Bioventus	62.94%
SMLR Semler Scientific	49.37%
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
AORT Artivion	6.30%
BVS Bioventus	33.50%
SMLR Semler Scientific	16.40%
TNDM Tandem Diabetes Care	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,800	48.76 million	45.68 million	Optionable
BVS Bioventus	950	84.09 million	55.92 million	N/A
SMLR Semler Scientific	120	15.29 million	12.78 million	Not Optionable
TNDM Tandem Diabetes Care	2,500	69.58 million	68.12 million	Optionable

SMLR, TNDM, AORT, and BVS Headlines

Recent News About These Companies

Tandem Diabetes Expands Insulin Delivery System to 12 New Countries

1 hour ago | finance.yahoo.com

Tandem Diabetes Care, Inc. Announces Tandem Mobi Automated Insulin Delivery System Is Now Available in Twelve International Markets

September 28 at 7:15 AM | marketscreener.comM

Tandem Diabetes expands Mobi insulin system overseas

September 28 at 7:15 AM | grafa.comG

Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

September 28 at 3:00 AM | businesswire.com

Tandem Diabetes Care(TNDM)获机构维持买入评级，目标价下调至28美元

September 26 at 5:26 PM | eeo.com.cnE

Tandem Diabetes Care (NASDAQ:TNDM) Stock Falls 6.7% After Analyst Downgrade

September 26 at 2:24 AM | americanbankingnews.com

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Target Cut by Truist Financial

September 26 at 1:42 AM | americanbankingnews.com

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 6.7% After Analyst Downgrade

September 24, 2026 | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Given New $28.00 Price Target at Truist Financial

September 24, 2026 | marketbeat.com

Truist Lowers Price Target on Tandem Diabetes Care to $28 From $31, Keeps Buy Rating

September 24, 2026 | marketscreener.comM

Is Tandem Diabetes Care (TNDM) Undervalued As Investors Weigh Its 34% One Year Return?

September 20, 2026 | finance.yahoo.com

Engineers Gate Manager LP Makes New Investment in Tandem Diabetes Care, Inc. $TNDM

September 20, 2026 | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from Brokerages

September 18, 2026 | marketbeat.com

Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

September 17, 2026 | zacks.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Up 5.6% - Should You Buy?

September 16, 2026 | marketbeat.com

Squarepoint Ops LLC Buys Shares of 217,386 Tandem Diabetes Care, Inc. $TNDM

September 13, 2026 | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 4.2% - Here's What Happened

September 11, 2026 | marketbeat.com

Tandem Diabetes Care: Stop Paying For Tomorrow's Profits - Strong Sell

September 11, 2026 | seekingalpha.com

Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued

September 10, 2026 | gurufocus.com

First Light Asset Management LLC Boosts Position in Tandem Diabetes Care, Inc. $TNDM

September 10, 2026 | marketbeat.com

Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

September 9, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMLR, TNDM, AORT, and BVS Company Descriptions

Artivion NYSE:AORT

$23.02 +0.39 (+1.72%)

Closing price 03:58 PM Eastern

Extended Trading

$22.34 -0.68 (-2.93%)

As of 07:30 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Bioventus NASDAQ:BVS

$14.02 +0.21 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$13.85 -0.17 (-1.23%)

As of 07:56 PM Eastern

Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Semler Scientific NASDAQ:SMLR

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

Tandem Diabetes Care NASDAQ:TNDM

$16.42 +0.70 (+4.45%)

Closing price 04:00 PM Eastern

Extended Trading

$16.66 +0.24 (+1.44%)

As of 07:36 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SMLR, TNDM, AORT, and BVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SMLR, TNDM, AORT, and BVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SMLR, TNDM, AORT, and BVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMLR, TNDM, AORT, and BVS Company Descriptions

Artivion NYSE:AORT

Bioventus NASDAQ:BVS

Semler Scientific NASDAQ:SMLR

Tandem Diabetes Care NASDAQ:TNDM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SMLR, TNDM, AORT, and BVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SMLR, TNDM, AORT, and BVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SMLR, TNDM, AORT, and BVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMLR, TNDM, AORT, and BVS Company Descriptions

Artivion NYSE:AORT

Bioventus NASDAQ:BVS

Semler Scientific NASDAQ:SMLR

Tandem Diabetes Care NASDAQ:TNDM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools